Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | NQO2 | P16083 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | METAP2 | P50579 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313313 | 0.84 | ACHE (0.61) | ACHEALDH1A1MAPTKMT2AGAA | |
| SCHEMBL13313310 | 0.84 | ACHE (0.61) | ACHEALDH1A1MAPTKMT2AGAA | |
| SCHEMBL3181469 | 0.84 | ACHE (1.00) | ACHEALDH1A1MAPTKMT2AGAA | |
| SCHEMBL13439504 | 0.81 | ACHE (0.85) | ACHEALDH1A1MAPTKMT2AGAA | |
| SCHEMBL13271195 | 0.81 | ACHE (0.75) | ACHEALDH1A1MAPTKMT2AGAA | |
| SCHEMBL13271231 | 0.79 | ACHE (0.65) | ACHEALDH1A1MAPTKMT2AGAA | |
| SCHEMBL20272058 | 0.78 | ACHE (0.69) | ACHEALDH1A1MAPTKMT2AGAA | |
| SCHEMBL345562 | 0.77 | ALDH1A1 (1.00) | ACHEALDH1A1MAPTKMT2AGAA | |
| SCHEMBL28063770 | 0.77 | ACHE (0.77) | ACHEALDH1A1MAPTKMT2AGAA | |
| SCHEMBL8604288 | 0.77 | MAPT (0.52) | ACHEALDH1A1MAPTKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958842-B2 | Substituted phenazines and methods of treating cancer and bacterial diseases | ADJUTEC PHARMA AS (NO) | 2024-04-16 | — | — | US | disclosed |
| US-20210292313-A1 | SUBSTITUTED PHENAZINES AND METHODS OF TREATING CANCER AND BACTERIAL DISEASES | Rongved, Pål (NO) | 2021-09-23 | — | — | US | disclosed |
| US-20210292313-A1 | SUBSTITUTED PHENAZINES AND METHODS OF TREATING CANCER AND BACTERIAL DISEASES | Rongved, Pål (NO) | 2021-09-23 | — | — | US | disclosed |
| US-11046678-B2 | Substituted phenazines and methods of treating cancer and bacterial diseases | Rongved, Pål (NO) | 2021-06-29 | — | — | US | disclosed |
| US-11046678-B2 | Substituted phenazines and methods of treating cancer and bacterial diseases | Rongved, Pål (NO) | 2021-06-29 | — | — | US | disclosed |
| US-20200095237-A1 | COMPOUNDS | Rongved, Pål (NO) | 2020-03-26 | — | — | US | disclosed |
| US-20200095237-A1 | COMPOUNDS | Rongved, Pål (NO) | 2020-03-26 | — | — | US | disclosed |
| EP-3555052-A1 | N-OXIDE HETEROCYCLES FOR USE IN THE TREATMENT OF CANCER AND BACTERIAL DISEASES | Rongved, Pål (NO) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109504-A1 | N-OXIDE HETEROCYCLES FOR USE IN THE TREATMENT OF CANCER AND BACTERIAL DISEASES | UNIVERSITETET I OSLO (NO) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018109504-A1 | N-OXIDE HETEROCYCLES FOR USE IN THE TREATMENT OF CANCER AND BACTERIAL DISEASES | UNIVERSITETET I OSLO (NO) | 2018-06-21 | — | — | WO | disclosed |
| WO-2017011730-A2 | PHENAZINE DERIVATIVES AS ANTIMICROBIAL AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| WO-2010057471-A1 | CHINOXALINE COMPOUNDS AND SEMICONDUCTOR MATERIALS | NOVALED AG (DE) | 2010-05-27 | — | — | WO | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| WO-1999052365-A1 | ANTICANCER AGENTS | ELI LILLY AND COMPANY (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958842-B2 | Substituted phenazines and methods of treating cancer and bacterial diseases | TLR5, TOP2A, SCN5A | ACHE 3930/4885ALDH1A1 2277/4885MAPT 1156/4885 |
| US-20210292313-A1 | SUBSTITUTED PHENAZINES AND METHODS OF TREATING CANCER AND BACTERIAL DISEASES | TLR5, TOP2A, SCN5A | ACHE 3930/4885ALDH1A1 2277/4885MAPT 1156/4885 |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | ACHE, PSEN1, PSEN2 | ACHE 1/4885ALDH1A1 703/4885MAPT 5/4885 |
| US-11046678-B2 | Substituted phenazines and methods of treating cancer and bacterial diseases | NRAS, ABCB11, APC | ACHE 1855/4885ALDH1A1 1861/4885MAPT 1448/4885 |
| US-20200095237-A1 | COMPOUNDS | MSR1, CA7, SLC7A5 | ACHE 2034/4885ALDH1A1 2061/4885MAPT 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.